(Q36197026)

English

Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Nicholas J Robert

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Mansoor N Saleh

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Devchand Paul

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Daniele Generali

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Laurent Gressot

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Mehmet S Copur

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Adam M Brufsky

7

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Susan E Minton

8

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Jeffrey K Giguere

9

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

John W Smith

10

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Paul D Richards

11

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Diana Gernhardt

12

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Xin Huang

13

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Katherine F Liau

14

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Kenneth A Kern

15

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

John Davis

16

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

language of work or name

0 references

publication date

11 April 2011

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Clinical Breast Cancer

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

11

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

82-92

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

1 October 2017

An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

1 October 2017

NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

1 October 2017

Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

1 October 2017

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

1 October 2017

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

1 October 2017

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

1 October 2017

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

1 October 2017

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

1 October 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

1 October 2017

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

1 October 2017

An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

2 July 2018

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

22 September 2018

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

22 September 2018

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

22 September 2018

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

22 September 2018

Serum insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

22 September 2018

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

22 September 2018

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

22 September 2018

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

22 September 2018

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

22 September 2018

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4617186

5 December 2018

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569994

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.CLBC.2011.03.005

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36197026&oldid=2004795408"